Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data
Executive Summary
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.
You may also be interested in...
Coronavirus Update: Indian Vaccine Makers Highlight US Component Constraints
A roundup of the latest global developments around COVID-19, including progress in Asia for Moderna's vaccine, promising results for a Lilly antibody combo, and new vaccine support moves by CEPI.
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Coronavirus Update: Lilly To Seek EUA For Olumiant
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.